Abstract: Novel compounds of the formula I in which W, X, Y, T, R1 and R2 are as defined in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders

Abstract: 1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ?CH— or ?N—, Y is —NH—, —NR4—, —S—, —O—, —CH?N—, —N?CH—, —N?N—, —CH?CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.

Abstract: The present invention is directed to compounds comprising a ring-fused quinoxalinyl moiety which inhibit the activity of Akt, a serine/threonine protein kinase.

Abstract: An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCl, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection site.

Abstract: The present invention relates to tricyclic pyridines compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof:

Abstract: Methods for inhibiting an inflammatory cytokine cascade in a patient are provided. The methods are directed to treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor.

Abstract: Compounds of formula (I) or (II) are described: where the groups are as defined in the description here below, the racemic mixtures, their individual enantiomers, their individual diastereoisomers, their mixtures, and their pharmaceutically acceptable salts. Said compounds are topoisomerase I inhibitors.

Abstract: The present invention provides compounds of the following structure, wherein R1-R9, R15, and n are defined herein. These compounds are useful in treating neurological disorders or complications due to stroke or head injury, and as neuroprotective and neuroregenerative agents.

Abstract: The invention relates to compounds of formula I in free or salt form, where R1 is a monovalent aromatic group having up to 10 carbon atoms, and R2 is a cycloaliphatic group having up to 8 ring carbon atoms. Compositions containing them, methods for their preparation and their use as pharmaceuticals are also described.

Abstract: The present invention addresses substituted thiophene derivatives, as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.

Abstract: The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

Abstract: A difluoroalkene derivative which is sufficiently effective in controlling various pests even when used in a small dose and is highly safe for crops, natural enemies to the pests, and animals; and an intermediate for the derivative.

Abstract: A thiadiazole compound of the formula (A): wherein R1 represents methyl, C3-C7 alkenyl, C2-C7 alkoxyalkyl, C2-C7 alkylthioalkyl, C4-C7 alkoxyalkoxyalkyl, C4-C7 alkylthioalkoxyalkyl, phenyl C1-C2 alkyl in which phenyl may be substituted, phenyloxy C1-C2 alkyl in which phenyloxy may be substituted, phenyl C2-C3 alkoxyalkyl in which phenyl may be substituted, or the substituent of the formula (B): wherein R3 represents C1-C3 alkyl, and R4 represents a hydrogen atom, methyl, ethyl or phenyl which may be substituted; and R2 represents phenyl C1-C4 alkyl in which phenyl may be substituted, pyridyl C1-C4 alkyl in which pyridyl may be substituted, or pyrimidyl C1-C4 alkyl in which pyrimidyl may be substituted; has an excellent arthropod pests controlling activity.

Abstract: This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, where Z is S, O or NH; and R, R1, R2 Ra, Rb, Rc, Rd, Z, A and B are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract: There is provided a series of substituted acyl guanidines of Formula (Ik) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

Abstract: Disclosed herein are methods and compositions related to compound 1 or a pharmaceutically acceptable salt, or a prodrug thereof (all of which are referred to hereafter, collectively or individually, as “compound 1”), which is an antagonist of a prostaglandin EP4 receptor, or is a prostaglandin EP4 antagonist. Also disclosed is a method comprising administering a prostaglandin EP4 antagonist to a mammal suffering from, or at risk of developing, a disease or condition selected from the group consisting of cancer, immunological disorders, neurodegenerative disorders, ocular diseases, hepatic diseases, renal diseases, septicemia, fibromyalgia, dermatological disorders, and antipyrexia.

Abstract: The present invention is directed to a method of treating action tremor or severe essential tremor. Action tremor includes essential tremor, postural tremor, drug-induced or toxic tremor, primary orthostatic tremor, dystonic tremor, neuropathic tremor, and cerebellar tremor. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of zonisamide, or a pharmaceutically acceptable salt thereof. The methods of the present invention are useful in reducing symptoms of tremor. The compounds of the present method can also be used in conjunction with other therapeutic agents commonly used to treat tremor thus enhancing the therapeutic effect of treating tremor.

Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

Abstract: Compounds of Formula I are useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein and have improved pharmacokinetic properties. These compounds may be used in methods of preventing and/or treating clotting disorders.

Abstract: The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

Abstract: The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. In particular, the ODC inhibitor difuoromethylornithine (DFMO) is disclosed as a useful pharmacological agent in the modulation and treatment of ALS. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.

Abstract: The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.

Abstract: The anti-angiogenic functions of a polysulfated, cyclic compound, ST104P, were investigated. ST104P exhibited excellent water solubility and low cytotoxicity to endothelial cells. ST104P potently inhibited the secretion of matrix metalloproteinase (MMPs) by endothelial cells. Moreover, ST104 also perturbed the migration and tube formation of endothelial cells. Application of ST104P abolished the neovascularization in chicken choroiallantoic membrane (CAM) in a dose-dependent manner. Besides, repeated administration of ST104P into Lewis lung carcinoma resulted in delayed tumor growth and prolonged the life span of tumor-bearing mice. These results indicated that ST104P inhibited angiogenesis and may hold promises for treatment of cancer and diseases or conditions caused by excessive angiogenesis.

Abstract: A graft reverse thermal hydrogel which does not show substantial loss of complex viscosity at and up to 20 degrees above the transition temperature upon autoclaving or aging. Other embodiments include the graft reverse thermal copolymer which can be dissolved in water to produce the graft reverse thermal hydrogel, a process for manufacturing the graft reverse thermal copolymer and hydrogel and applications for the stable graft reverse thermal hydrogel.

Abstract: The present invention relates to a stable emulsion of an immiscible fluid and of an aqueous phase having a determined pH value. The emulsion is optimized in that it comprises an ionic surfactant and a polyampholytic polymer whose charge depends on the pH value. The respective amounts of surfactant and of polymers are determined according to the charges. Stabilization or destabilization of the emulsion is adjusted by controlling the pH value. The invention also relates to a method of stabilizing and destabilizing an emulsion comprising a surfactant combined with an ampholytic polymer.

Abstract: A catalyst and process for converting carbon dioxide into oxygenates. The catalyst comprises copper, zinc, aluminum, gallium, and a solid acid.

Abstract: Disclosed are novel compositions for the preparation of void-containing articles comprising a polymer matrix and a voiding agent The voiding agent comprises at least one first polymer and at least one second polymer, which are selected on the basis of physical properties such as glass transition temperature, tensile modulus, melting point, surface tension, and melt viscosity. Shaped articles such as sheet, film, bottles, tubes, labels, and sleeves may prepared from these compositions. Also disclosed are polyester shrink films prepared using a voiding agent comprising a novel blend of cellulosic and olefinic polymers. The resulting shrink films have better opacity, lower density, reduced shrink force, and improved printability as compared with most standard voiding agents. The films are useful for sleeve label and other shrink film applications and their lower density allows them to be readily separated from soft drink bottles, food containers and the like during recycling operations.

Abstract: A process of preparing water soluble or water swellable polymer comprising the steps, (a) forming an aqueous mixture comprising, (i) a water soluble ethylenically unsaturated monomer or blend of monomers and, (ii) an ultra violet initiator, (b) effecting polymerisation by subjecting the aqueous mixture formed in step (a) to polymerisation conditions to form a polymer of said monomer or monomer blend, (c) subjecting the polymer formed in step (b) to ultra violet light radiation, characterised in that the polymerisation step (b) is conducted substantially in the absence of ultra violet radiation. In one preferred aspect the ultra violet initiator is distributed throughout the polymer formed in step (b). In another preferred aspect the step (c) is conducted ultra violet light at an intensity of up to 500 milli Watts/cm2.

Abstract: This invention relates generally to compositions and systems for forming biomaterials containing a transient colorant for visualizing tissue or surgical materials coated with such biomaterials, to methods of using such compositions as bioadhesives, for tissue augmentation, in the prevention of surgical adhesions, for coating surfaces of synthetic implants, as drug delivery matrices, for ophthalmic applications, and in other applications.

Abstract: An ink jet ink composition of water, a humectant, and a hyperbranched polymeric dye of a hyperbranched polymer having a dye chromophore pendant on the polymer chain or incorporated into the polymer backbone.

Abstract: It is an object of the present invention to provide an ink jet recording ink with excellent storage stability, with which no mold or other microbes will be generated over an extended period. The ink jet recording ink of the present invention contains water and a colorant comprising a pigment encapsulated by a polymer having a carboxyl group, wherein this ink jet recording ink is characterized by containing at least methylisothiazolone and octylisothiazolone.

Abstract: The present invention relates to a splayed material comprising a layered material splayed with a particle having a diameter equal to or less than 3 micrometers. Another embodiment of the invention includes an article comprising a matrix and a layered material splayed with a polymeric particles dispersed in a medium. The invention also relates to methods for preparing these materials via mixing, milling and emulsifying a solvent borne polymer with a surfactant. A further method describes a method for preparing a nanocomposite from a splayant particle prepared by combining an emulsion polymerization monomer and a surfactant dispersible in a medium wherein the monomer is not dispersible in the medium.

Abstract: There are provided a resin composition comprising a crosslinking component with a weight average molecular weight of 1,000 or less having a plurality of styrene groups and represented by the following formula: wherein R is a hydrocarbon skeleton, each of R1s is a hydrogen atom or a hydrocarbon group, each of R2, R3 and R4 is a hydrogen atom or an alkyl group, m is an integer of 1 to 4, and n is an integer of 2 or more, at least one high-molecular weight compound, an inorganic filler, and at least one treating agent for said inorganic filler; its cured product; and a prepreg, a laminate sheet having a conductor layer, and a multilayer printed wiring board obtained by processing the conductor layer of the laminate sheet into wiring.

Abstract: The invention relates to a novel flame retardant dispersion for thermoplastic and thermoset polymers, comprising, as component A, a phosphinic salt of the formula (I), and/or a diphosphinic salt of the formula (II), and/or polymers of these, where R1 and R2 are identical or different and are C1-C6-alkyl, linear or branched, and/or aryl; R3 is C1-C10-alkylene, linear or branched, C6-C10-arylene, -alkylarylene, or -arylalkylene; M is Mg, Ca, Al, Sb, Sn, Ge, Ti, Zn, Fe, Zr, Ce, Bi, Sr, Mn, Li, Na and/or K; m is from 1 to 4; n is from 1 to 4; x is from 1 to 4, and, as component B, a nitrogen-containing synergist or a phosphorus/nitrogen flame retardant, and, as component C, a liquid compound.

Abstract: A stabilizer against hydrolysis, which can solve conventional problems of a carbodiimide compound compounded in an ester-group-containing resin or a biodegradable plastic as a stabilizer against hydrolysis, such as poor heat resistance and a coloring problem due to yellowing, and can provide enhanced resistance against hydrolysis, and a thermoplastic resin composition of an ester-group-containing resin or a biodegradable plastic containing the same.

Abstract: The present invention relates to compositions and preparative process of partially or fully neutralized mixtures of carboxylate functionalized ethylene high copolymers or terpolymers (Mw between 80,000 and 500,000) with carboxylate functionalized ethylene low copolymers (Mw between 2,000 and 30,000) and organic acid salts and injection or compression molded applications such as golf ball components thereof.

Abstract: Dendron ligands or other branched ligands with cross-linkable groups were coordinated to colloidal inorganic nanoparticles, including nanocrystals, and substantially globally cross-linked through different strategies, such as ring-closing metathesis (RCM), dendrimer-bridging methods, and the like. This global cross-linking reaction sealed each nanocrystal within a dendron box to yield box-nanocrystals which showed dramatically enhanced stability against chemical, photochemical and thermal treatments in comparison to the non-cross-linked dendron-nanocrystals. Empty dendron boxes possessing a very narrow size distribution were formed by the dissolution of the inorganic nanocrystals contained therein upon acid or other etching treatments.

Abstract: A dip-forming latex obtained by copolymerization of (a) 50-89.5 weight parts of a conjugated diene monomer, (b) 10-40 weight parts of an ethylenically unsaturated nitrile monomer, (c) 0.5-10 weight parts of an ethylenically unsaturated acid monomer and (d) 0-20 weight parts of other copolymerizable ethylenically unsaturated monomer (the total of these monomers is 100 weight parts), wherein the copolymerization is initiated with a monomer mixture comprising at least 80 wt. % of (a), at least 50 wt. % of (b), 10-90 wt. % of (c) and least 80 wt. % of (d), and thereafter, the remainders of monomers are added to a polymerization system to continue copolymerization. This latex gives a dip-formed article exhibiting good softness of touch, high tensile strength and good retention of close fittingness.

Abstract: There are provided a polypropylene resin composition comprising: (i) 10 to 99% by weight of a specific propylene copolymer (X), (ii) 0 to 60% by weight of a specific copolymer (Y), and (iii) at least one member selected from the group consisting of 1 to 30% by weight of a specific propylene polymer (W) and 0.1 to 3 parts by weight of a nucleating agent (N); and a film comprising said polypropylene resin composition, or a laminated film having a layer comprising said polypropylene resin composition.

Abstract: A chlorosulphonated ethylene-?-olefin copolymer having a chlorine content of 0.5-20% by weight and a glass transition temperature in differential scanning calorimetry (DSC) of ?50° C. or lower and being crystalline. The chlorosulphonated ethylene-?-olefin copolymer is obtained by chlorinating a crystalline ethylene-?-olefin copolymer having a density of 890 kg/m3 or lower, obtained by copolymerizing ?-olefin comprising a hydrocarbon having 4 or more carbon atoms, with ethylene, and then chlorosulphonating the chlorinated copolymer.

Abstract: Polyethylene glycol aldehyde compounds are provided. Methods of making and using such compounds, as well as chemical intermediates are also provided.

Abstract: Process for the preparation of a functionalized polymer containing an additive, in which process there is formed a compound that contains, besides at least one blocked isocyanate group, a free amino, hydroxy or carboxy group; this compound is linked to an additive via the free amino, hydroxy or carboxy group in the additive; this additive linked to the compound mentioned is contacted with a polymer that contains at least one free amino or hydroxyl group, at a temperature above the polymer's melting point and at least above 150° C., such that the blocked isocyanate group reacts with the free amino or hydroxy group of the polymer to form the functionalized polymer. The invention also relates to the intermediate products formed in the process and in the preparation thereof. Lastly, the invention relates to functionalized polymers and polymer compositions containing the functionalized polymer.

Abstract: Self-adhesive addition-crosslinking silicone compositions, contain two adhesion promoters, a first, multinuclear aromatic compound containing at least one moiety of aliphatic unsaturation, and a low viscosity organopolysiloxane having at least one terminal, silicon-bonded hydrogen. The addition curable materials exhibit strong adhesion to substrates, even substrates which have exhibited problematic adhesion to silicone elastomers in the past.

Abstract: Supported catalyst systems are provided comprising (a) a transition metal compound, (b) a non aluminoxane activator comprising, and (c) a support material comprising an inorganic metal oxide, inorganic metal halide or polymeric material or mixtures thereof characterised in that the support material has been pretreated with an SO4 containing compound. The preferred transition metal compounds are metallocenes and the SO4 containing compound is typically sulphuric acid. The supported catalyst systems show improved activity and also may reduce fouling in gas phase fluidised bed processes.

Abstract: A process is described for the preparation of ethylene copolymers having a wide molecular weight distribution, characterized in that it is carried out in the presence of meso- and rac-stereoisomeric mixtures of metallocene compounds having general formula (I), wherein A? and A?, the same or different, are a radical of the ??5-tetrahydroindenyl type (Ia)

Abstract: Methods for making polyolefins are disclosed. One method comprises polymerizing an olefin in the presence of a catalyst system comprising a single-site complex, an agglomerated metal oxide/clay support-activator, and an ionic borate. Including an ionic borate with the support-activator provides an unexpected boost in catalyst activity and gives polyolefins with high molecular weight and improved comonomer incorporation. In another method of the invention, an olefin is polymerized in the presence of an indenoindolyl metal alkylated complex and an agglomerated metal oxide/clay support-activator. Use of alkylated indenoindolyl complexes with the support-activators provides improved activity compared with metal halides.

Abstract: A crosslinkable resin composition is provided which can be a forming material having excellent adhesion to metals and excellent heat resistance. The crosslinkable resin composition comprises; a cycloolefin resin (A) obtained through metathesis polymerization of a cycloolefin monomer in the presence of a compound having two or more vinyl groups in the molecule, and a radical generating agent (B). A crosslinked resin molded product is obtained by crosslinking such a crosslinkable resin composition through heating.

Abstract: A cross-linkable and cross-linked organosilicon polymer which is prepared from a mixture of a reactive polysiloxane resin having both reactive carbon-carbon double bonds and silicone-hydrogen groups, characterized by alternating structures of polycyclic polyene residue and cyclic (or tetrahedral) polysiloxane residue, and either vinyl terminated fluorine-containing polysiloxane or vinyl terminated phenyl-substituted siloxane. In an alternative embodiment, the polymer comprises a mixture of vinyl terminated phenyl-substituted polysiloxane and vinyl functional fluorosilicone elastomer with the cross-linkable and cross linked organosilicon polymer.

Abstract: A reaction product comprises a polyester-polycarbonate comprising a polyester unit and a polycarbonate unit, a polycarbonate polymer, and a transesterification catalyst. The reaction product has a haze of less than 1.7% as measured at a thickness of 3.2 mm according to ASTM D1003-00. A thermoplastic composition comprising the reaction product and articles formed from therefrom are disclosed. A method of forming the reaction product is also disclosed.